Introduction
The availability of a suitable HLA-matched donor is one of the major limitations to the widespread application of allogeneic hematopoietic stem cell transplantation (HSCT).
For only 30% of patients a matched related donor, and for up to 70% a matched unrelated donor can be found. 1 In ethnical minorities or if the aggressive course of the disease requires fast identification of a suitable donor, donor search can be even more difficult. Since virtually every patient has a suitable haploidentical related donor within the family, a successful strategy for haploidentical allogeneic hematopoietic stem cell transplantation (haplo-HSCT) would eliminate the "lacking donor" problem.
However, initial trials of haplo-HSCT were complicated by a high incidence of graftversus-host-disease (GVHD), engraftment failure, and infectious complications resulting in unacceptable high treatment related morbidity and mortality (TRM). 2 Graft rejection and GVHD is primarily mediated by host and donor T-cells. Therefore attempts to overcome the HLA-barrier were focused on strategies for effective host and graft T-cell depletion. The Perugia group pioneered an approach of graft T-cell depletion by positive selection of CD34+ stem cells combined with transplantation of a megadose of these cells (>10x10 6 CD34+ cells/kg body weight) in order to overcome the HLA barrier in the haploidentical setting. 3, 4 The strategy allowed successful haplo-HSCT with a low rate of GVHD and a promising event free survival for patients transplanted in complete remission (CR). 5 However, this strategy for haplo-HSCT relies on intensive myeloablative conditioning regimens and CD34-selection for T-cell depletion which may lead to high toxicity and slow immune reconstitution. The incidence of non relapse mortality (NRM) reported is up to 57% mainly related to toxicities and infections. 6 In our own experience of haplo-HSCT using such approach, we observed a high toxicity of the conditioning regimen, high NRM, slow engraftment namely of platelets and delayed immune reconstitution. 7 A delayed engraftment was observed particularly with CD34-doses <8x10 6 /kg body weight. 8 This precludes elderly, heavily pre-treated and comorbid patients from such approach. New strategies of graft manipulation using immunomagnetic cell depletion aim to improve engraftment, making haplo-HSCT feasible even after reduced intensity conditioning (RIC) and without megadoses of CD34+ cells. Based on the promising experiences gained at St. Judes Children's Research Hospital /Memphis in the pediatric population 9, 10 , a new regimen using graft CD3/CD19 depletion with anti-CD3-and anti-CD19-coated microbeads on a CliniMACS device was developed. This approach allows the transplantation of an "untouched" graft product in contrast to CD34 selected stem cells which are coated with CD34-specific microbeads, potentially altering the characteristics of the stem cells transplanted. CD3/CD19
depleted grafts not only contain CD34+ stem cells, but also CD34-negative progenitors, natural killer (NK)-, dendritic-and other graft-facilitating-cells [11] [12] [13] [14] [15] [16] and enable haplo-HSCT after RIC using fludarabine, thiothepa and melphalan. T-and Bcell depletion was employed to reduce the risk of GVHD and to prevent EBVlymphoproliferative disease (LPD). In addition to chemotherapy the anti-CD3 mAb OKT-3 was used in order to deplete remaining host-T-cells, avoiding graft rejection.
In contrast to the frequently used polyclonal anti-thymocyte globulin (ATG), OKT-3 spars incoming engraftment facilitating cells such as NK-cells.
Using CD3/CD19 depleted haploidentical grafts and RIC with fludarabine, thiotepa and melphalan we observed sustained and in comparison to CD34-selection accelerated engraftment without a megadose of CD34+ stem cells 7, 17 even in a elderly and heavily pretreated patient population. We here report the results of a prospective multicenter phase II study evaluating this approach.
Design and Methods

Study Protocol and Centers
The responsible for approval of trials in HSCT. All patients signed informed consent.
Primary objective was the evaluation of TRM on day +100 after haplo-HSCT. As secondary objectives engraftment, toxicity, infections, immune reconstitution, GVHD, rate of relapse and event-free survival (EFS) were evaluated.
Eligibility Criteria
Inclusion criteria were patients with high risk hematologic diseases curable with allogeneic HSCT with the diagnoses of acute myeloblastic leukemia (AML), 
CD3/CD19 depletion, conditioning regimen and transplantation
CD3/CD19-depletion was performed by negative selection using the automated CliniMACS device as described (Miltenyi Biotec, Bergisch-Gladbach, Germany). 
Monitoring of patients for engraftment, chimerism, immune reconstitution, disease and donor lymphocyte infusions
Hematopoietic donor cell chimerism in mononuclear cells (MNC) was monitored in all patients using microsatellite markers as described. 20 Additionally in some patients flow cytometry based evaluation of chimerism T-and NK-cell chimerism was used. was assessed using criteria of the international working group. 22 GVHD was assessed and graded as described. 
Statistical analysis
Sample size calculation for this exploratory phase II study was based on an expected TRM/NRM of 25% until day +100. With a sample size of 60 patients a two sided 95%
confidence interval (CI) will extend 11% from the observed proportion. Therefore a sample size of n=60 was considered to be sufficient to evaluate TRM/NRM until day +100 as primary objective of this phase II study. 24 Following factors were included in the regression models: gender, age (<55 yrs. versus ≥ 55 years), prior HSCT, achievement of CR prior to haplo-HSCT (yes versus no), grade of acute GVHD (aGVHD) (<3 versus ≥ 3), chronic GVHD (cGVHD), diagnosis (AML versus other). A landmark analysis was used to assess the impact of cGVHD on survival. 25 As landmark the time point of the first occurrence of cGVHD in our cohort at 8 months was used. All patients who were alive and in CR at 8 months after haplo-HSCT were included in this analysis.
Results
Patients and Donors
Sixty-one patients were enrolled in the study. Patient characteristics are shown in Table 1 . Patients were heavily pretreated with a median of 4 (range, 1-9) lines of prior chemotherapies. Median EBMT-HSCT risk-score was 6 (range, 5-7). 26, 27 All donor-recipient pairs had at least a two-loci mismatch and 38 patients had in addition a KIR-mismatch in GVH direction using the KIR-ligand model. 11 If a choice of multiple donors was available, the donor with a KIR-mismatch was chosen.
CD3/CD19 depletion
T-and B-cell depletion was 4.1 log. The grafts contained 1.48% CD34+ cells due to the high content of non-CD34+ cells such as NK-cells, monocytes, granulocytes and antigen presenting cells. Average recovery of CD34 positive cells was 59%. Table S1 (Online supplementary) illustrates details on graft composition and CD3/CD19 depletion characteristics in 26 patients treated within the study in Tuebingen.
Graft content
All patients received HSCT with CD3/CD19 depleted haploidentical grafts. The 
Engraftment
All but 5 patients engrafted with full donor chimerism by day 7-126 after haplo-HSCT.
Two of these patients died due to NRM within 14 days after HSCT before engraftment could occur. Median time to engraftment was 12 (range, 9-50) days to >500 granulocytes/µL and 11 (range, 7-38) days to >20000 platelets/µL (Online supplementary Figure S1 ). In 51 patients data on transfusional support was available. 50 of 51 patients (98%) required platelet support (median 7, range 0-53).
48 of 51 (94%) patients received red blood cell transfusions (median 8, range 0-46).
Four cases of secondary graft rejection were observed, two of them rescued by a consecutive haplo-HSCT with CD3/CD19 depleted cells from an alternative haploidentical donor.
Immune reconstitution
Detailed studies on immune reconstitution were performed and results were published previously in detail. 28 In the study reported here immune reconstitution was 
Toxicity, infections, GVHD and NRM
The regimen was well tolerated with maximum acute toxicity being grade 2-3 mucositis, nausea and loss of appetite. Initially, using 200 mg/m 2 fludarabine, we observed severe neurotoxicity in 4 patients. In consequence, fludarabine dose was reduced to 150 mg/m 2 . NRM in the first 100 days was 14/61 (23%) and 25/61 (41%) after two years. Table 3 shows the causes of NRM and time to death after haplo-HSCT. Cumulative incidence (CI) of NRM adjusted for relapse as competing risk was 23% on day 100 (95% CI 0.147-0.359) and 42% at 2 years (95% CI 0.291-0.538) ( Figure 1A ). Causes of infectious deaths are shown in Table 2 . Table S2 of the supplementary appendix details immune reconstitution and infectious deaths of patients treated in Tuebingen. Incidence of grade II-IV° aGVHD was 46% and 18% of cGVHD (n=11, limited n=7, extensive n=4). The occurrence of acute and chronic GVDH in relation to T-cell dose in the graft is illustrated in Figure S3 of the online supplementary appendix. In patients receiving a graft with CD3+ T-cells >7,5x10 4 /kg the proportion of GVHD is increased as shown in Figure S4 A Figure 1B ). Kaplan-Meier estimate 2-year OS was 29% in AML, 0% in ALL and 50% in NHL patients (Figure 2A ). For patients with AML in CR at time of haplo-HSCT 2-year estimated OS was 32% ( Figure 2B ). All but one patient transplanted for advanced ALL died either due to relapse (n=4) or NRM (n=3).
Cumulative incidence of relapse/progression adjusted for competing risk NRM at 2 years was 31% (95%CI 0.197-0.433). Patients with limited cGVHD had a better 2-year survival with 67% versus 24% without any cGVHD (p=0.0864) as analyzed with a landmark analysis at 8 months after haplo-HSCT ( Figure 2C ). Graft CD3 content (>75000 CD3+ cells/kg versus <75000 CD3+ cells/kg) impacted OS as follows:
Kaplan-Meier estimate for 1-year OS was 35% with the higher versus 45% with the lower T-cell content and 21% versus 33% for 2-year OS (p= 0.27) ( Figure 2D ).
KIR Mismatches
Using the KIR-ligand model In the subgroup of patients with AML (n=38) we observed an association between KIR-MM and an impaired survival (Kaplan-Meier estimate 2-year OS of 19% with KIR-MM versus 65% without KIR-MM, p=0.01).
Chimerism
Complete donor chimerism was reached in 54 patients after a median of 15 days after HHSCT (range 7-124), 7 patients died before reaching a full donor chimerism.
Prior engraftment of neutrophils full chimerism was documented in 12 of 60 patients. 
Donor lymphocyte infusions
Eleven patients received CD3+ T-lymphocytes (one to four times) as DLI (ten because of relapse (n=6) or mixed chimerism (n=4) and one patient as antigenspecific T-cells because of virus reactivation) ranging from 2x10 4 to 3x10 8 /kg at varying time points after haplo-HSCT (day +0-100, n=4; day +100-200, n=6; day +200-300, n=4; day +300-600, n=4). Two patients developed aGVHD after receipt of DLI. Seven patients died due to relapse, two because of infections and two patients receiving DLI for mixed chimerism are alive and in CR.
Risk factors for survival and non relapse mortality
In a univariate analysis of risk factors for OS, EFS and NRM several possible factors could be identified (Table 4) . Improved OS and EFS was associated with the presence of cGVHD (p=0.019 and p=0.010, respectively). In multivariate cox regression analysis adjusted for competing risk relapse/progression male gender was associated with a decreased hazard ratio (HR) for NRM (HR 0.4, p=0.046) while age ≥55 years was associated with an increased HR of 2.8 (p=0.030).
Discussion
The study reported here evaluated a new approach for haplo-HSCT aiming at improved engraftment even with grafts containing lower numbers of CD34 positive stem cells and allowing the use of a RIC regimen. The regimen proved to be of low toxicity enabling its use even in an older or heavily pretreated patient population including patients who received preceding allogeneic or autologous HSCT. Various other groups have confirmed the feasibility and low toxicity of this RIC for allogeneic HSCT. [30] [31] [32] [33] In consequence, the median age of the CD3/19 patients reported here is about a decade older than previously reported adult patients receiving Haplo-HSCT with CD34 selected grafts.
5,34
The significant influence of graft composition and conditioning regimen on engraftment is illustrated by the fast engraftment kinetics observed. This also translated into low transfusion requirements. Although these engraftment kinetics are similar to data reported by Aversa et al. after haplo-HSCT with CD34-selected grafts (median 11 days to ANC>1000/µL and 15 days to PLT>25000/µL) 5 it is remarkable that our cohort received a much lower median CD34-dose with 7.0x10 6 CD34+/kg versus 13.8x10 6 CD34+/kg in the Aversa study. We saw sustained engraftment with CD34-doses as low as 3. selected grafts, one has to consider the different conditioning regimens used. RIC as used in this study may allow faster immune recovery. To draw definite conclusions, a prospective study comparing both methods of graft manipulation for haplo-HSCT after a similar conditioning regimen would be necessary.
We observed a higher incidence and degree of GVHD after haplo-HSCT with CD3/CD19 depleted grafts compared to the reported low incidence of <10% in patients receiving haplo-HSCT with CD34 selected grafts. 5 This may be related to the higher median T-cell dose transplanted in our patients. The aGVHD observed was mainly moderate skin GVHD, readily responsive to steroid therapy. With this regimen doses <5x10 4 CD3+ cells/kg seem safe even without GVHD prophylaxis, doses of NRM adjusted for relapse as competing risk was 23% on day 100 and 42% at 2 years. This may seem to be high for a RIC, but the median EBMT risk score in the study population was 6 which is associated with an estimated NRM of approximately 45%. 26, 27 Our NRM is comparable to the data of Aversa et al. with CD34 selected grafts who reported 37% for patients transplantated in remission and 44% for patients transplanted in relapse. Ciceri et al. reported NRM ranging 36 to 66% depending on disease status at haplo-HSCT. 43 Although these previous NRM rates were seen after myeloablative conditioning our patients were about a decade older and almost all with advanced disease. Furthermore most of the NRM was related to infections and GVHD and not to toxicity of the conditioning.
The estimated OS of 41% at one year and 28% at two years in our study is promising given the high risk profile of the patient treated. The patients with the biggest benefit from the approach described here were patients with NHL and AML in remission with a two year survival of 50% and 32%, respectively. Even AML patients not in CR at time of haplo-HSCT had a 2-year OS of 25%, which might be related to additional NK-alloreactivity. Aversa et al. reported an EFS of 48% at two years for patients with AML in remission at time of haplo-HSCT but only 4% for patients transplanted in relapse. 5 Ciceri et al. summarizing the EBMT experience on haplo-HSCT with CD34-selected grafts after myeloablative conditioning described a two year leukemia free survival in AML of 1% for advanced patients and 21% in patients in CR2. 43 Furthermore, comparing these studies to our own data one has to consider several factors in our cohort with a potential negative impact on outcome or risk of relapse:
we used RIC in a patient population which was more than 10 years older. Our patients were more heavily pretreated with a median of 4 lines of chemotherapy and one third of the patients after preceding autologous or allogeneic HSCT. Only one of our patients was in CR1 but with high cytogenetic risk.
Currently, various strategies are investigated to improve immune reconstitution after haplo-HSCT using T-cell repleted 44, 45 and depleted grafts. Strategies to enhance immune reconstitution after T-cell depleted haplo-HSCT include DLI 28 , suicide-geneengineered DLIs 46 , photodynamically purged DLI 47 but also the use of donor Tregs early after haplo-HSCT. 48 Our group is currently evaluating selective depletion of αβ-T-lymphocytes 49 for haplo-HSCT. In pilot patients we observed that the residual δγ-Tcells in the graft may enhance T-cell recovery and induce GVL effects without GVHD.
A prospective multicenter study with this approach is currently in preparation.
In conclusion, this study shows that haplo-HSCT with CD3/CD19 depleted grafts and RIC is feasible. The regimen described allows haploidentical HSCT in an older and heavily pretreated patient population and enables long term disease free survival. 
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